Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
LVMH Reclaims Title of Europe’s Most Valuable Stock From Novo
It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.
Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
EconoTimes13h
Denmark PM Responds to Trump’s Greenland Remarks Amid Geopolitical Tensions
Denmarks Prime Minister Mette Frederiksen has called for a meeting with the nations business leaders after U.S.
5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
devdiscourse1d
Denmark's Diplomatic Push: Navigating Greenland Tensions
Denmark's Prime Minister Mette Frederiksen initiated discussions with business leaders in response to U.S. President-elect ...
MLive7m
Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...